CD34 antibody | MEC14.7
Rat anti Mouse CD34 antibody, clone MEC14.7 (MCA1825) used for the identification of CD34 expressing cells in CRC liver metastases in mouse liver by immunohistochemistry on formalin fixed paraffin embedded tissue sections following heat mediated antigen retrieval in citrate buffer.
Image caption:
Differences in blood vessel morphology between tumor periphery and center.A: Formalin fixed liver sections with CRC liver metastases were stained with antibodies to CD34 (staining of endothelial cells on immature vessels). Scale bar=200μm. Inset 1 depicts tumor vessels (arrows) in the tumor center staining strongly for the CD34 endothelial marker. Inset 2 depicts tumor vessels (arrows) in the tumor periphery staining weakly for the CD34. Inset 3 depicts host vessels (arrows) being co-opted by the tumor displaying weak or no CD34 staining. B: Quantification of CD34 positive vessels in tumor center and tumor periphery expressed as CD34 positive vessels /mm2. Black bars = tumor periphery, Grey bars = tumor center. Significantly more CD34 positive vessels are seen in the tumor center (*P<0.001). Quantification of αSMA pericyte association with tumor vessels revealed a significantly greater number in the tumor periphery compared to the tumor center (* P<0.0001, Black bars = tumor periphery, Grey bars = tumor center. Data is expressed as mean value ± SEM, with n≥5 for each group. Data was not normally distributed and non-parametric analysis was performed and statistical significance determined using Kruskal Wallis and Mann-Whitney U test.
From: Nguyen L, Fifis T, Malcontenti-Wilson C, Chan LS, Costa PN, Nikfarjam M,Muralidharan V, Christophi C.
Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.
BMC Cancer. 2012 Nov 15;12:522.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD34 antibody, clone MEC14.7 (MCA1825) used for the identification of CD34 expressing cells in CRC liver metastases in mouse liver by immunohistochemistry on formalin fixed paraffin embedded tissue sections following heat mediated antigen retrieval in citrate buffer.
Image caption:
Changes in endothelial cells and vessel morphology following OXi4503 treatment. Mice were treated with a single IP dose of OXi4503 (100mg/kg) at 16 days after tumor induction. Tissues were collected at one hour, 24 hours and five days after treatment. Formalin fixed liver sections were stained with anti-CD34 antibody to visualize tumor vessels. (A), Control tumor, arrow indicates a patent tumor vessel; 1hr OXi4503, arrows indicate endothelial cells rounding up and detaching from the vessel basement membrane; 1hr OXi4503, EC apoptosis, the section was doubly immunostained for CD34 and active caspase-3 (apoptosis marker), to visualise endothelial cells undergoing apoptosis (arrows); 24hrs OXi4503 center, arrow points at a totally occluded tumor vessel; 24hrs OXi4503 periphery, arrow indicates patent tumor vessel; 5 days OXi4503 , center, demonstrating regenerating tumor vessels surrounded by proliferating tumor cells; Single staining magnification scale bar=50μm, double staining magnification scale bar=25μm. (B), Enumeration of vascular endothelial cell apoptosis show significant differences between the tumor center and periphery at one and 24 hours after treatment (*P <0.001); (C), Quantification of tumor vascular changes following OXi4503 treatment. Vascular density decreased significantly in the tumor center (**P<0.0001), but not the periphery (P=0.173) at 24 hours after treatment. Tumor revascularization at day five is significantly higher compared to the untreated control both at tumor center and the periphery (*P=0.001). Results are mean values ± SEM, (n≥5). Black bars = tumor periphery, Grey bars = tumor center.
From: Nguyen L, Fifis T, Malcontenti-Wilson C, Chan LS, Costa PN, Nikfarjam M,Muralidharan V, Christophi C.
Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.
BMC Cancer. 2012 Nov 15;12:522.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD34 antibody, clone MEC14.7 (MCA1825) used to identify endothelium in mouse liver sections by immunohistochemistry of formalin fixed, paraffin embedded tissue sections following antigen retrieval.
Image caption:
Differences in blood vessel density following different treatment regimens. a Formalin fixed liver sections with CRC liver metastases were stained with antibodies to CD34 (staining of endothelial cells). First column Scale bar = 200μm. Second column depicts magnified inset regions of first column images. Scale bar = 50μm. T = live tumor, NT = necrotic tumor. Second inset in the OXi4503 treatment indicates central tumor vessels recovering ahead of live tumor repopulation. Arrow in the Sunitinib treatment indicates intact central vessel surrounded with live tumor cells. Arrows in the combination treatment show liver damage. b Quantification of CD34 positive vessels. Data is expressed as mean value ± SEM, with n ≥ 5 for each group. Data was not normally distributed and non-parametric analysis was performed and statistical significance determined using Mann-Whitney U test. (OXi4503 vs control *P <0.001, Sunitinib and combination vs control *P <0.001 and Sunitinib vs combination # P = 0.001)
From: Nguyen L, Fifis T, Christophi C.
Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
BMC Cancer. 2016 Jul 26;16(1):533.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD34 antibody, clone MEC14.7 (MCA1825) used to evaluate tumor angiogenesis in CBA mice by immunohistochemistry on formalin fixed, paraffin embedded tissue sections.
Image caption:
Effect of kinin receptor inhibition on tumor angiogenesis in CBA mice induced with CRLM. Tumor blood vessels were visualised by immunostaining for CD34 endothelial cell marker (brown staining). a,c&e magnification 5×, a,d&f (corresponding insets) magnification 20×, 0 to 100 images at 20× magnification of stained tumor from each mouse were taken in a pre-determined systematic fashion. CD34 positive blood vessels were counted using Image ProPlus 6. SSR240612 (SSR) and FR173657 (FR) treatment significantly reduced tumor angiogenesis compared to control (CTRL) shown in g. Results are presented as group mean value ±SD, (n=6) (*p < 0.001; **p <0.0001 compared to control)
From: da Costa PLN, Wynne D, Fifis T, Nguyen L, Perini M, Christophi C.
The kallikrein-Kinin system modulates the progression of colorectal liver metastases in a mouse model.
BMC Cancer. 2018 Apr 4;18(1):382.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
FITC conjugated Mouse anti Human CD34 antibody, clone 3A6 (MCA1825PE) used to evaluate CD34 expression on bone-marrow derived mesenchymal stem cells by flow cytometry
Image caption:
Immunophenotypic and differentiation characterization of BM-MSCs of aplastic anemia (AA) patients. (a) Representative flow cytometric histograms showing immunophenotype of BM-MSCs of AA patients and controls.
From: Chaturvedi CP, Tripathy NK, Minocha E, Sharma A, Rahman K, Nityanand S.
Altered Expression of Hematopoiesis Regulatory Molecules in Lipopolysaccharide-Induced Bone Marrow Mesenchymal Stem Cells of Patients with Aplastic Anemia.
Stem Cells Int. 2018 Oct 17;2018:6901761.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD34 antibody, clone MEC14.7 (MCA1825) used for the demonstration of endothelial cells in islet grafts by immunohistochemistry of formalin fixed, paraffin embedded tissue sections.
Image caption:
Vascular density of pelleted and manually dispersed islet grafts.
Immunostaining of microvascular endothelial cells (ECs) with CD34 antibodies in pelleted (a) and dispersed (b) islet grafts. Original magnification ×400, scale bars 25 μm.
From: Rackham CL, Jones PM, King AJF (2013)
Maintenance of Islet Morphology Is Beneficial for Transplantation Outcome in Diabetic Mice.
PLoS ONE 8(2): e57844.
doi: 10.1371/journal.pone.0057844
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD34 antibody, clone MEC14.7 (MCA1825) used for the demonstration of endothelial cells in islet grafts by immunohistochemistry of formalin fixed, paraffin embedded tissue sections.
Image caption:
Vascular density of matrigel-implanted islets.
CD34 immunostaining of microvascular endothelial cells (ECs) in pelleted islet grafts (a) and matrigel-implanted islet grafts (b) at 1 month post transplantation. Original magnification ×400, scale bars 25 μm.
From: Rackham CL, Jones PM, King AJF (2013)
Maintenance of Islet Morphology Is Beneficial for Transplantation Outcome in Diabetic Mice.
PLoS ONE 8(2): e57844.
doi: 10.1371/journal.pone.0057844
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Rat anti Mouse CD34:FITC
Rat anti Mouse CD34:Low Endotoxin
Rat anti Mouse CD34
Rat anti Mouse CD34:RPE
- Product Type
- Monoclonal Antibody
- Clone
- MEC14.7
- Isotype
- IgG2a
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| MCA1825FA | F | 50 µg |
|
|
| MCA1825F | F | 0.1 mg |
|
|
| MCA1825FB | F | 0.5 mg |
|
|
| MCA1825EL | F IP P | 0.5 mg |
|
|
| MCA1825T | F IP P | 25 µg |
|
|
| MCA1825GA | F IP P | 0.1 mg |
|
|
| MCA1825 | F IP P | 0.25 mg |
|
|
| MCA1825PE | F | 100 Tests |
|
Rat anti Mouse CD34 antibody, clone MEC14.7 recognizes the murine CD34 cell surface antigen, which is expressed by endothelial cells and by haematopoietic stem cells. This antibody recognizes a neuraminidase sensitive epitope. As in the human system, CD34 antibodies in the mouse demonstrate slightly different staining patterns depending on their fine specificity. Rat anti Mouse CD34 antibody, clone MEC14.7 appears to recognize a subset of the stem cell population recognized by clone RAM34, and it is thought that this is due to differences in the epitope recognized by the two antibodies.
Product Details
- Target Species
- Mouse
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Reconstitution
- Reconstitute with 1.0 ml distilled water
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
- None present
- Preservative Stabilisers
0.09% Sodium Azide - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Carrier Free
- Yes
- Carrier Free
- Yes
- Immunogen
- T-end.1, a pMT transformed endothelial cell line.
- Approx. Protein Concentrations
- Pack Size: 50 µg, 0.1 mgIgG concentration 0.1 mg/mlPack Size: 0.5 mgIgG concentration 0.5 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Approx. Protein Concentrations
- Pack Size: 25 µg, 0.25 mgIgG concentration 1.0 mg/mlPack Size: 0.1 mgIgG concentration 1 mg/ml
Storage Information
- Storage
- Pack Size: 50 µg, 0.1 mgStore at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.Pack Size: 0.5 mgStore at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at -20oC only.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- UniProt
- Q64314
- Entrez Gene
- Cd34
- GO Terms
- GO:0016021 integral to membrane
- GO:0005576 extracellular region
- GO:0005737 cytoplasm
- GO:0009897 external side of plasma membrane
- GO:0043199 sulfate binding
- GO:0050900 leukocyte migration
- Regulatory
- For research purposes only
Applications of CD34 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | 1/5 | Neat Pack Size: 0.1 mg 1/10 Pack Size: 0.5 mg |
|
| Flow Cytometry | |||
| Immunohistology - Paraffin | 1/20 | 1/200 | |
| Immunoprecipitation | |||
| Flow Cytometry | 1/10 Pack Size: 25 µg, 0.25 mg 1/25 Pack Size: 0.1 mg |
1/20 Pack Size: 25 µg, 0.25 mg 1/50 Pack Size: 0.1 mg |
|
| Immunohistology - Paraffin | 1/20 | 1/200 | |
| Immunoprecipitation | 2ug/ml | 10ug/ml | |
| Flow Cytometry | Neat | 1/5 |
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR ( BUF041A/B). - Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity fc receptors. This may be reduced by using SeroBlock FcR (BUF041A/B).
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Rat IgG2a Negative Control:FITC | MCA1212F | F | 100 Tests |
|
|
| Rat IgG2a Negative Control:Low Endotoxin | MCA1212EL | F | 0.5 mg |
|
|
| Rat IgG2a Negative Control | MCA1212 | E F | 1 ml |
|
|
| Rat IgG2a Negative Control:RPE | MCA1212PE | F | 100 Tests |
|
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
|
| Antigen Retrieval Buffer, pH8.0 | BUF025C | P | 50 ml | ||
| Antigen Retrieval Buffer, pH8.0 | BUF025A | P | 500 ml | ||
| Antigen Retrieval Buffer, pH8.0 | BUF025C | P | 50 ml | ||
| Antigen Retrieval Buffer, pH8.0 | BUF025A | P | 500 ml | ||
| Mouse Seroblock FcR | BUF041A | F | 0.1 mg |
|
|
| Mouse Seroblock FcR | BUF041B | F | 0.5 mg |
|
Product Specific References
Source Reference
-
Garlanda, C. et al. (1997) Characterization of MEC 14.7, a new monoclonal antibody recognizing mouse CD34: a useful reage for identifying and characterizing blood vessels and hematopoietic precursors.
Eur J Cell Biol. 73 (4): 368-77.
References for CD34 antibody
-
Winding, B. et al. (2002) Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.
Clin Cancer Res. 8 (6): 1932-9. -
Nguyen, L. et al. (2012) Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.
BMC Cancer. 12: 522. -
Morison, N.B. et al. (2007) The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women.
Reproduction. 133: 309-21. -
Chen, L. et al. (2010) Roles of tetrahydrobiopterin in promoting tumor angiogenesis.
Am J Pathol. 177: 2671-80. -
Ager, E.I. et al. (2010) Targeting the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases.
Cancer Cell Int. 10: 19 -
Chabot, S. et al. (2011) A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.
J Exp Med. 208: 973-86. -
Chen, J. et al. (2011) Circulating endothelial progenitor cells and cellular membrane microparticles in db/db diabetic mouse: possible implications in cerebral ischemic damage.
Am J Physiol Endocrinol Metab. 2011 Jul;301(1):E62-71. -
Chen, J. et al. (2012) Transfusion of CXCR4-primed endothelial progenitor cells reduces cerebral ischemic damage and promotes repair in db/db diabetic mice.
PLoS One. 7 (11): e50105. -
Ouji, Y. & Yoshikawa, M. (2016) Maintenance of Skin Epithelial Stem Cells by Wnt-3a In Vitro.
Methods Mol Biol. 1516: 279-88. -
Nguyen, L. et al. (2016) Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
BMC Cancer. 16 (1): 533. -
Vávrová, J. et al. (2012) Irradiated stem cells and ageing of the haematopoietic system.
Radiat Environ Biophys. 51 (2): 205-13. -
DaCosta, P.L.N. et al. (2018) The kallikrein-Kinin system modulates the progression of colorectal liver metastases in a mouse model.
BMC Cancer. 18 (1): 382. -
Danielyan, L. et al.. (2020) Cell motility and migration as determinants of stem cell efficacy
EBioMedicine. 60:102989. -
Rackham, C.L. et al. (2013) Maintenance of islet morphology is beneficial for transplantation outcome in diabetic mice.
PLoS One. 8 (2): e57844.
